Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.

Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) ...

Obesity affects nearly one in three adults in England, with disproportionate burden among disadvantaged groups and widening disparities since the COVID-19 pandemic. Increasing rates among individuals ...

June 22 () - Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from ‌Haisco Pharmaceutical Group, targeting complement-mediated diseases and ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company’s research organization SAN DIEGO--(BUSINESS ...